Delivery of Compounds. Metabasis will promptly identify and deliver to Sankyo [***] information on the chemical structure of, data generated on, and (if so requested) reasonable quantities (for research and preclinical pharmacology use) of, any potential New Back-up Compound. Upon termination of this Agreement by Sankyo pursuant to Section 8.2, Metabasis will promptly identify and deliver to Sankyo (for research and preclinical pharmacology use) [***] of the quantity of any potential New Back-up Compound in the possession of Metabasis.
Delivery of Compounds. MTI will promptly identify and deliver to Sankyo [***] information on the structure of, data generated on, and (if so requested) reasonable quantities (for research and preclinical pharmacology use) of, any Research Compound [***], Recommended Compound or Candidate Compound, for development and evaluation by Sankyo in accordance with this Agreement. The parties shall discuss in good faith any requested arrangements for the synthesis and supply to Sankyo of larger quantities of materials for use under the Research Program. Upon the occurrence of an event which would entitle to Sankyo to terminate this Agreement pursuant to Section 1.42, MTI will promptly identify and deliver to Sankyo (for research and preclinical pharmacology use) [***] fifty percent (50%) of the quantity of any Research Compound then in the possession of MTI.
Delivery of Compounds. Axys shall use commercially reasonable efforts to deliver the Compounds in the Library to Warnxx-Xxxxxxx xxxording to the following schedule: [*] Compounds to be delivered by the end of [*], and the remainder to be delivered by Axys [*] thereafter at an annual rate of approximately [*] Compounds per year. If Axys is able to produce and deliver the Compounds at a faster rate than contemplated above, then, if mutually agreed with Warnxx-Xxxxxxx, Xxys may deliver such Compounds as they become available for delivery. The Compounds shall be delivered in 96 well plates with an 88 well array format with approximately [*] (which is approximately[*]) of each Compound present in the shipment, or in such other reasonable format as is reasonably requested by Warnxx-Xxxxxxx, xxovided that any additional cost to Axys required to prepare or ship such other format shall be paid by Warnxx-Xxxxxxx. Xxch shipment shall be accompanied by a confidential description of the identity and structure of each Compound in such shipment. Accompanying each shipment will be the results of the analysis of each Compound, performed by Axys according to the method of analysis set forth in Exhibit B attached hereto.
Delivery of Compounds. Subject to Section 2.2(b), AAT shall use [ * ] to deliver the Compounds to Allergan according to the following schedule: [ * ] to be delivered by [ * ]; an additional [ * ] to be delivered by [ * ] (with such deliveries to be made on a quarterly basis as determined by the Technology Committee); and an additional [ * ] to be delivered by [ * ] (with such deliveries to be made on a quarterly basis as determined by the Technology Committee). The Compounds shall be delivered in [ * ], or any other [ * ]. Risk of loss for and title to the Compounds provided by AAT to Allergan under this Agreement shall pass from AAT to Allergan [ * ]. AAT shall deliver a certificate of analysis with each Library specifying the results of analysis to show conformance with the specifications set forth in Exhibit A.
Delivery of Compounds. (a) SpringWorks will deliver, at its sole cost, the SpringWorks Compound DDP (INCOTERMS 2010) to GSK’s, or its designee’s location as specified by GSK (“Delivery” with respect to such SpringWorks Compound). Title and risk of loss for the SpringWorks Compound shall transfer from SpringWorks to GSK at Delivery. All costs associated with the subsequent transportation, warehousing and distribution to Sub-Study sites of SpringWorks Compound after Delivery takes place shall be borne by GSK. For the avoidance of doubt, if prior to Delivery the SpringWorks Compound for any reason or in any way becomes lost, damaged, destroyed or becomes unable to comply with applicable Specifications, SpringWorks shall be obligated to replace the same at its sole cost and to use commercially reasonable efforts to do so as soon as practicable in order to cause the least disturbance to the conduct and timelines of the Sub-Study.
(b) GSK is solely responsible, at its sole cost, for supplying (including all Manufacturing, acceptance and release testing) the GSK Compound for the Sub-Study, and the subsequent handling, storage, transportation, warehousing and subsequent distribution to Sub-Study sites of the GSK Compound supplied hereunder. For purposes of this Agreement, the “Delivery” of a given quantity of the GSK Compound shall be deemed to occur when such quantity is packaged for shipment to a Sub-Study site.
Delivery of Compounds. 5.1 All Compounds supplied to Makerere by Upstream for performance of the Services shall be transported in compliance with all applicable import, export, customs, and other laws and regulations in relation to the transportation of such Compounds.
5.2 Upstream shall clearly label any toxic or dangerous Compounds and will notify Makerere prior to shipping of the Compounds of all proper handling procedures as well as furnish any Material Safety Data Sheets for such Compounds.
5.3 Makerere shall not be responsible for damage of any nature, which may arise, from transportation of the Compounds to Makerere or from Makerere’s return of unused Compounds to Upstream at Upstream’s request.
Delivery of Compounds. (a) SpringWorks will deliver, at its sole cost, the SpringWorks Compound for use in the activities to be conducted by GSK under the Development Plan [***] (INCOTERMS 2020) to GSK’s, or its designee’s location as specified by GSK (“Delivery” with respect to such SpringWorks Compound). Title and risk of loss for the SpringWorks Compound shall transfer from SpringWorks to GSK at Delivery. All costs associated with the subsequent transportation, warehousing and distribution to Clinical Study sites of SpringWorks Compound after Delivery takes place shall be borne by GSK. For the avoidance of doubt, if prior to Delivery the SpringWorks Compound for any reason or in any way becomes lost, damaged, destroyed or becomes unable to comply with applicable Specifications, SpringWorks shall be obligated to replace the same at its sole cost and shall use Commercially Reasonable Efforts to do so as soon as practicable in order to cause the least disturbance to the conduct and timelines of the activities under the Development Plan.
(b) GSK is solely responsible, at its sole cost, for supplying (including all Manufacturing, acceptance and release testing) the GSK BCMA Products for the activities under the Development Plan, and the subsequent handling, storage, transportation, warehousing and subsequent distribution of the GSK BCMA Products supplied hereunder.
Delivery of Compounds. 5.1 All Compounds supplied to ProvLab by Upstream for performance of the Services shall be transported in compliance with all applicable import, export, customs, and other laws and regulations in relation to the transportation of such Compounds.
5.2 Upstream shall clearly label any toxic or dangerous Compounds and will notify ProvLab prior to shipping of the Compounds of all proper handling procedures as well as furnish any Material Safety Data Sheets for such Compounds.
5.3 ProvLab shall not be responsible for damage of any nature, which may arise, from transportation of the Compounds to ProvLab or from ProvLab’s return of unused Compounds to Upstream at Upstream’s request.
Delivery of Compounds. In accordance with Section 15 of the Original --------------------- Agreement, Abbott has delivered to ICOS [ * ] compounds (the "Supplied Compounds") and related information.
Delivery of Compounds. Microcide will provide to Daiichi [*] Compounds in 96-well microtitre plate format (100 microliters at a concentration of 10 milligrams per milliliter in 100% DMSO) at a mutually acceptable date which is not expected to be later than June 30, 1997. Microcide will also provide structure and source files (SD files), and a description of plate well locations. Microcide will subsequently provide, in shipments of [*] Compounds each, the following supplies of synthetic compounds in dry powder format: [*] Compounds - 10-15 mg each [*] Compounds - 5 mg each The last shipment of the supplies of synthetic compounds in dry powder format is expected to be made prior to December 31, 1997. Microcide will use its best efforts to provide SD files and description of plate well locations and to carry out the weighing and labeling of the Compounds hereunder.
